|
Synonyms: BIIB-033 | BIIB033
Compound class:
Antibody
Comment: Opicinumab is a monoclonal antibody which acts as a functional antagonist of the neural protein, LINGO1 [2-3]. Opicinumab was investigated for its clinical utility in diseases with underlying immune-driven demyelination.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A BLAST search of patented peptide sequences reveals a 100% match between the variable heavy chain region of opicinumab and SEQ ID NO: 5 from patent US8058406 B2, and another identical match between the variable light chain of the antibody and the patent's SEQ ID NO: 13 [2]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H et al.. (2017)
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol, 16 (3): 189-199. [PMID:28229892] |
|
2. Mi S, Pepinsky B, Graff C. (2011)
Composition comprising antibodies to LINGO or fragments thereof. Patent number: US8058406 B2. Assignee: Biogen Idec Ma Inc.. Priority date: 09/11/2016. Publication date: 15/11/2011. |
|
3. Mi S, Pepinsky B, Shao Z, Garber EA, Miklasz SD, Graff C. (2012)
Sp35 antibodies and uses thereof. Patent number: US8128926 B2. Assignee: Biogen Idec Ma Inc.. Priority date: 09/01/2007. Publication date: 06/03/2012. |
|
4. Mi S, Pepinsky RB, Cadavid D. (2013)
Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs, 27 (7): 493-503. [PMID:23681979] |
|
5. Pepinsky RB, Arndt JW, Quan C, Gao Y, Quintero-Monzon O, Lee X, Mi S. (2014)
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy. J Pharmacol Exp Ther, 350 (1): 110-23. [PMID:24756303] |
|
6. Shams PN, Plant GT. (2009)
Optic neuritis: a review. Int MS J, 16 (3): 82-9. [PMID:19878630] |
|
7. Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L et al.. (2014)
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm, 1 (2): e18. [PMID:25340070] |
